VIVALDI2: A 5-day Dry Immersion Study on 20 Healthy Male Volunteers

Sponsor
Centre National d'Etudes Spatiales (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05493176
Collaborator
European Space Agency (Other)
20
1
1
4
5

Study Details

Study Description

Brief Summary

Dry immersion (DI) is a ground-based model of prolonged conditions of simulated microgravity. Dry immersion involves immersing the subject in water covered with an elastic waterproof fabric. As a result, the immersed subject, who is freely suspended in the water mass, remains dry. Within a relatively short duration, the model can faithfully reproduce most physiological effects of actual microgravity, including centralization of body fluids, support unloading, and hypokinesia.

The main objective of the present study is to investigate the physiological effects of 5 days of dry immersion in 20 healthy male subjects, and to obtain DI-in-Men Reference Dataset. A set of measurements will assess the changes in the cardiovascular, neuro-ophthalmological, hematological, metabolic, sensorimotor, immune, muscle and bone systems.

Condition or Disease Intervention/Treatment Phase
  • Other: Dry immersion
N/A

Detailed Description

Space flights have shown the possibilities and limitations of human adaptation to space. For the last 50 years, results have shown that the space environment and microgravity in particular, cause changes that may affect the performance of astronauts. These physiological changes are now better known: prolonged exposure to weightlessness can lead to significant loss of bone and muscle mass, strength, cardiovascular and sensory-motor deconditioning, immune, hormonal and metabolic changes .

Moreover, recently a new suite of physiological adaptations and consequences of space flight has been acknowledged. Indeed, after long flights, some astronauts present persistent ophthalmologic changes, mostly a hyperopic shift, an increase in optic nerve sheath diameter and occasionally a papillary oedema now defined by National Aeronautics and Space Administration (NASA) as Spaceflight-Associated Neuro-ocular Syndrome (SANS). Some of these vision changes remain unresolved for years post-flight. This phenomenon has most likely existed since the beginning of human space flight but is just recently being recognized as a major consequence of adaptation to microgravity.

Overall, spaceflight induces physiological multi-system deconditioning which may impact astronauts' efficiency and create difficulties upon their return to normal gravity. Understanding the underlying mechanisms of these processes and developing efficient countermeasures to prevent, limit or reverse this deconditioning remain important challenges and major priorities for manned space programs.

The space agencies are actively engaged in studying the physiological adaptation to space environment through studies on board the International Space Station (ISS) but also on the ground. Indeed, considering the limited number of flight opportunities, the difficulties related to the performance of in-flight experiments (operational constraints for astronauts, limited capabilities of in-flight biomedical devices), ground-based experiments simulating the effects of weightlessness are used to better understand the mechanisms of physiological adaptation, design and validate the countermeasures. Different methods are used to simulate microgravity on Earth. However, two approaches, -6° head-down bed rest (HDBR) and dry immersion (DI) have provided possibilities for long-term exposures with findings closest to those seen with a weightless state. They produce changes in body composition (including body fluid redistribution), cardiovascular and skeletal muscle characteristics that resemble the effects of microgravity.

The common physiological denominator is the combination of a cephalad shift of body fluids and reduced physical activity. Being similar in their effects on the human body, these models, however, differ in their specifics and acting factors. The HDBR, as the name implies, implicates a long (from several weeks to a year) stay in the supine position, the head tilted down by -6° from the horizontal plane. HDBR is the most frequently used ground-based simulation for gravitational unloading of the human body in western countries.

Unlike bed rest, dry immersion provides a unique opportunity to study the physiological effects of the lack of a supporting structure for the body. Dry immersion means immersing the subject into thermoneutral water, while covered with a special elastic free floating waterproof fabric. The subject, surrounded by the tarp and "freely suspended" in the water mass, remains dry. During horizontal immersion, pressure forces are distributed nearly equally around the entire surface of the body (only the head and neck are not entirely supported by water). The absence of mechanical support of specific anatomic zones during immersion creates a state akin to weightlessness called "supportlessness". Physiological changes under DI develop more rapidly and are more profound than under HDBR . This advanced ground-based model is extremely suited to test countermeasures for microgravity-induced deconditioning and physical inactivity-related pathologies.

In 2015, DI facility has been installed at the Space Clinic in Toulouse (France), and a first in Europe three-day dry immersion study was carried out in 12 healthy male volunteers. That study demonstrated an important headward fluid transfer with a significant dilatation of the jugular veins, an increase in venous blood velocities and intracranial pressure, as well as ophthalmological changes consistent with a presumable increase in intracranial pressure at the head at over 20 mmHg (normal values 7 to 15 mmHg), which confirms that dry immersion is a good model to simulate the effects of fluid transfer. In 2019, a second dry-immersion experiment, this time lasting 5 days, was conducted in 18 healthy male volunteers. The goal was to quantify the effect of venoconstrictive thigh cuffs, used for 10 hours/day as a countermeasure, on the time course and extent of DI-induced alterations in body fluids, cephalic circulation, fundus, and brain. These two studies have sparked the interest in the dry immersion model.

Indeed, the European Space Agency (ESA) has decided to include this model in the research programs it promotes on the effects of weightlessness. As a first step, ESA decided to carry out a standardization work like the one done on the bedrest model. ESA tasked a group of European experts to design a first study and the tests that would need to be carried out to better understand and validate the model.

Few studies conducted to date have investigated gender differences in the astronaut population.

The small number of female astronauts may be part of the reason why scientific data are lacking to draw valid conclusions about possible gender differences. However, if women currently constitute only about 12% of astronauts (only 72 women out of 596 astronauts as of December 2021), they are and will be more and more represented in crews. They now constitute 30% of American crews and NASA (US space agency) has announced gender parity for crews on future lunar missions. It is therefore essential to study the physiological changes induced by weightlessness in both sexes, and to develop efficient sex-specific countermeasures. The expert group has therefore concluded that two different studies with the same design should be carried out, one in women and one in men, to obtain a comparable dataset. An immersion period of 5 days was determined to induce the physiological changes they wish to study. A battery of tests has thus been defined by this expert group based on standard tests carried out in bedrest studies (Bedrest Standard Measurements), supplemented by additional tests to further investigate the model and to acquire a better understanding of the time course of the physiological changes in both sexes.

This work has started in 2021 with a first study, conducted in women during a 5-day immersion period (awaiting publication). The next step is to realize a similar set of measurements in men, to standardize the dry immersion model taking into account sex differences.

This study falls within this context and will be the first ESA dry immersion study carried out in men. Its objective is to obtain a standardized dataset for DI in men, which will serve as a basis for the development and evaluation of countermeasures to support future space missions. The main physiological systems will be explored before, during and after the 5 days of immersion through a battery of specific tests and measurements. The results will be analyzed by scientists specializing in each field in order to better understand the dry immersion model, to compare its effects with those of the bedrest model and those of spaceflight. Comparison with results obtained in the female population will be a major part of the analysis. The clinical (adverse effects, comfort of subjects) and operational aspects are also part of the secondary objectives of the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Standardization of the Dry Immersion Model Used as a Ground-based Model to Mimic Weightlessness. Phase 2: a 5-day Dry Immersion Study on 20 Healthy Male Volunteers (VIVALDI2)
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dry immersion

5 days of dry-immersion

Other: Dry immersion
Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.

Outcome Measures

Primary Outcome Measures

  1. Change in orthostatic tolerance [At baseline and five days of 5 days of dry immersion]

    Orthostatic tolerance will be assessed during a Lower Body Negative Pressure test (LBNP test)

  2. Change in peak aerobic power (VO2max test) [At baseline and the first day of recovery]

    Exercise capacity wil be assessed by graded cycling on sitting ergometer until exhaustion

  3. Change in plasma volume [At baseline and five days of dry immersion]

    Plasma volume (L) will be assessed by the carbon monoxide-rebreathing method

  4. Change in fluid shift distribution towards the cardiac and cephalic region [At baseline, the first day to quantify the short term effect and the fifth day of dry-immersion to quantify the long term effect of fluid shift]

    The consequences of the fluid shift on the cardiac and cephalic area will be assessed by quantifying the right and left Jugular veins volumes (mL), as well as the left ventricle diastolic/systolic volumes (mL) by ultrasound.

  5. Change in vascular endothelium integrity [At baseline and during the five days of the dry-immersion period]

    Vascular endothelium integrity will be assessed by blood parameters of vascular and endothelial integrity. Global change of endothelial state will be estimated using several biomarkers, including zonulin, cell adhesion molecules (E-selectin, L-selectin, CD146), growth factors (VEGF, VEGFR-1), glycocalyx breakdown products (syndecan-1, hyaluronic acid, heparan sulfate).

  6. Change in circadian rhythms of blood pressure [At baseline and during the five days of the dry-immersion period]

    Continuous 24-h recording of systolic and diastolic blood pressure will be performed by a Non Invasive Blood Pressure system (SOMNOtouch™NIBP) designed for ambulatory continuous measurements

  7. Change in lower limb veins functions [At baseline and four days of dry-immersion and one day of recovery]

    Venous compliance of lower limbs will be assessed by plethysmography

  8. Change in body fluid compartments by bioelectrical impedance analysis [At baseline and during five days of dry-immersion]

    Extracellular, intracellular and total body water will be estimated by bioimpedance

  9. Change in muscle strength [Before dry immersion and after one day of recovery]

    Muscle strength will be assessed from single leg isometric maximal voluntary contraction on the knee extensors & flexors, the plantarflexors and dorsiflexors. The Isometric Torque will be measured in Nm. The peak of the three maximal attempts will be recorded for strength measures

  10. Change in muscle fatigue [Before dry immersion and after one day of recovery]

    Muscle fatigability will be assessed during a submaximal isometric knee extension contraction held for 30 seconds at 50% of the baseline Maximal Voluntary Contraction (MVC) value

  11. Change in muscle volume at calf level [At baseline and five days of dry-immersion]

    Muscle dehydration, eventual atrophy and fatty degeneration will be measured by quantitative Dixon MRI sequences at calf level

  12. Change in contraction time [At baseline and five days of dry immersion]

    Contraction time will be assessed during a measurement using the tensiomyography method in the following muscles: vastus lateralis, Gastrocnemius medialis and Biceps femoris of dominant leg / arm.

  13. Change in serum bone formation markers [At baseline and during the 5 days of dry-immersion]

    Change in bone-specific Alkaline Phosphatase (bAP, µg/L) and procollagen type I N-terminal propeptide (P1NP, µg/L) will be assessed by chemiluminescence immunoassay

  14. Change in serum bone resorption markers [At baseline and during the 5 days of dry-immersion]

    Change in C-terminal cross-linked telopeptide of type I collagen (CTx, pmol/L) and N-terminal cross-linked telopeptide of type I collagen (NTX, pmol/L) will be assessed by chemiluminescence immunoassay

  15. Change in serum cartilage synthesis biomarkers [At baseline and during the 5 days of dry-immersion]

    Change in serum CP II and in human cartilage glycoprotein-39 (YKL-40) concentrations

  16. Change in serum cartilage degradation biomarkers [At baseline and during the 5 days of dry-immersion]

    Change in serum Cartilage Oligomeric Matrix Protein (COMP) and fragments or propeptide of type II collagen (C2C, C1,2C, Coll-2-1) concentrations

  17. Change in urine cartilage degradation biomarkers [At baseline and during the 5 days of dry-immersion]

    Change in C-telopeptide of type II collagen (CTX-II) and nitrated form of peptide of the α-helical region of type II collagen (Coll-2-1NO2) concentrations

  18. Change in Resting Metabolic Rate (RMR) [At baseline and 5 days of dry-immersion]

    RMR will be measured by indirect calorimetry technique

  19. Change in nitrogen balance [At baseline and 5 days of dry-immersion]

    Nitrogen balance is a measure of nitrogen input minus nitrogen output. Nitrogen intake is calculated with a nutrition software. Protein oxidation measured in the 24-Hour urine collection estimates nitrogen output

  20. Change in fat and lean body mass measured by dual energy x-ray absorptiometry (DEXA) [At baseline and 5 days of dry-immersion]

    Dual energy x-ray absorptiometry is a standard clinical technique to assess fat (g) and lean (g) body mass.

  21. Change in glucose tolerance (Oral Glucose Tolerance Test) [At baseline and 5 days of dry-immersion]

    Glucose and insulin levels will be measured at baseline (fasting) and 30, 60, 90, and 120 minutes after drinking within 5 min a water solution containing 75 g of glucose

  22. Change in Core temperature [At baseline and during the 5 days of dry immersion]

    Measured by electronic ingestible temperature capsules (e-Celsius Performance)

  23. Change in height [Before, during and after the 5 days of dry immersion]

    Measured in supine and standing position

  24. Change in mid cerebral artery (MCA) blood flow velocity [At baseline and 5 days of dry immersion]

    Transcranial Doppler measurements

  25. Change in mood [Before, during and after 5 days of dry-immersion]

    Change in mood is assessed using the Profile of Mood States (POMS) questionnaire. POMS questionnaire gives 6 measures of mood: Tension/anxiety, Depression, Anger/hostility Dynamism, Fatigue, Confusion A Total Mood Disturbance (TMD) score is calculated by summing the totals for the negative subscales (tension, depression, fatigue, confusion, anger) and then subtracting the totals for the positive subscale (vigor /esteem-related affect).

  26. Change in affective states [Before, during and after 5 days of dry-immersion]

    Positive and Negative Schedule (PANAS) questionnaire will be used to assess the intensity of positive and negative affective states. PANAS self-report questionnaire consists of two 10-item scales to measure both positive and negative affects Each item is rated on a five-point Likert Scale, ranging from 1 = Not at all to 5 = Extremely, to measure the extent to which the affect has been experienced in a specified time frame. Positive affects: scores can range from 10 - 50 with higher scores representing higher levels of positive affect. Negative affects: scores can range from 10 - 50 with higher scores representing higher levels of negative affect.

  27. Change in sleep quality [Before, during and after 5 days of dry-immersion]

    Pittsburgh Sleep Dairy (PghSD) will be used to assess sleep perceived quality. The PghSD is an instrument with separate components to be completed at bedtime and waketime. The following parameters are registered or assessed: Bedtime, waketime, sleep latency, wake after sleep onset, total sleep time, mode of awakening and ratings of sleep quality, mood, and alertness on wakening, as well as daytime information on naps, exercise, meals and caffeine, tobacco and medications use.

  28. Change in psychological state: mental health [Before, during and after 5 days of dry-immersion]

    General Health Questionnaire-28 (GHQ-28) will be used to assess psychological well-being and capture distress GHQ-28 gives an overall total score and 4 scores for 4 subscales: Somatic symptoms, Anxiety/insomnia, Social dysfunction, Severe depression. Higher scores indicate higher levels of distress

  29. Change in coping strategies [Before, during and after 5 days of dry-immersion]

    Brief Cope Questionnaire is designed to measure effective and ineffective ways to cope with a stressful life event, and will be used to assess coping strategies. The Brief Cope is a shortened form (28 items) of the Carver and Scheier COPE inventory. There are 14 coping strategies. These strategies can be then gathered in two main categories : approach coping and avoidance coping.

  30. Change in cerebral autoregulation [At baseline and 5 days of dry-immersion]

    Transcranial Doppler measurements of mid cerebral artery blood flow velocity will allow to determine cerebral autoregulation

  31. Change in Intra Cranial Pressure (ICP) [At baseline, during and after 5 days of dry-immersion]

    ICP changes will be monitored through OtoAcoustic Emissions (OAE)

  32. Change in optic nerve sheath diameter (ONSD) considered as an indirect marker for intracranial pressure (ICP) estimation [At baseline, during and after 5 days of dry-immersion]

    The optic nerve sheath diameter (ONSD) variations will be measured by echography

  33. Change in the optic nerve fibers thickness [At baseline and five days of dry-immersion]

    Thickness of the optic nerve fibers will be measured by Optical Coherence Tomography (OCT)

  34. Change in intraocular pressure (IOP) [At baseline, during and after five days of dry-immersion]

    IOP measured by applanation

  35. Change in visual acuity [At baseline and five days of dry-immersion]

    Far and near visual acuity are tested uncorrected, or if applicable with own correction with digital acuity system

  36. Change in visual field [At baseline and five days of dry-immersion]

    Visual field measured by standard automated perimetry

  37. Change in the anatomical characteristics of the eye (optical biometry) [At baseline and five days of dry-immersion]

    Optical biometry measured by partial coherence interferometry

  38. Change in the central corneal thickness [At baseline and five days of dry-immersion]

    Central corneal thickness on a single point on the cornea measured by Ultrasonic pachymetry

  39. Change in the retina by non-mydriatic fundus retinography [At baseline and five days of dry-immersion]

    Non-mydriatic fundus retinography allows a fundus photography to be taken and thus a color image of the papilla, retinal vessels and macula

  40. Change in the cornea topography [At baseline and five days of dry-immersion]

    Cornea topography measured by corneal topography equipment (like Pentacam). The elevation topography according to Scheimpflug principle allows the mapping of the anterior and posterior surface of the cornea.

  41. Change in cerebral structures and in venous circulation of the brain by MRI [At baseline and five days of dry-immersion]

    Visualization of cerebral structures and intracranial venous system will be performed by MRI coupled with injection of gadolinium

  42. Change in walking balance [At baseline and the first day of recovery]

    Walking balance will be assessed by Dynamic Gait Index, specific parameter is: total Score (range 0-24). Higher scores mean a better outcome

  43. Change in standing balance [At baseline and the first day of recovery]

    Standing balance will be assessed by posturography eyes open and eyes closed on a platform covered with 12-cm thick medium density foam

  44. Change in motion sickness susceptibility [At baseline, during and after 5 days of dry immersion]

    Assessed by the Motion Sickness Susceptibility Questionnaire Short form (MSSQ-Short). MSSQ-Short scores possible range from minimum 0 to maximum 54, the maximum being unlikely. Higher scores means a higher motion sickness susceptibility

  45. Change in thrombotic and fibrinolytic processes [Before, during and after 5 days of dry immersion]

    Thrombotic and fibrinolytic processes will be assessed by the following four coagulation values: i) plasma levels of tissue factor (TF), the physiological trigger for the coagulation cascade, by using the assay Actichrome Tissue factor ELISA from American Diagnostica (Pfungstadt, Germany); ii) Endogenous thrombin potential, an appropriate method to assess the coagulability of a given plasma sample, by using calibrated automated thrombography (CAT, Thrombinoscope BV, Maastricht, the Netherlands); iii) tissue-Plasminogen activator (tPA), by using the assay IMUBIND tPA ELISA kit from American Diagnostica (Pfungstadt, Germany); iv) thromboelastometry (TEM, coagulation analyzer from Matel Medizintechnik, Graz, Austria), providing a kinetic analysis of the clot formation process and of clot dissolution by the fibrinolytic system.

  46. Change in respiratory volumes [At baseline, the 1st day of dry immersion and following 5 days of dry immersion]

    Change in Forced vital capacity (FVC, L), Tidal Volume (TV, L), Inspiratory reserve Volume (IRV, L), Expiratory reserve volume (ERV, L) will be assessed using spirometry

  47. Change in respiratory flows [At baseline, the 1st day of dry immersion and following 5 days of dry immersion]

    Change in Forced expiratory volume in 1 second (FEV1, L/s) and in Peak expiratory flow (PEF, L/min), will be assessed using spirometry

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy male volunteer (see below the description of medical tests and laboratory analysis performed at the selection visit),

  • Age 20 to 40,

  • No overweight nor excessive thinness with BMI (weight Kg/ height m2) between 20 and 26,

  • Height between 158cm and 185 cm,

  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination): in particular, free from any chronic disease or any acute infectious disease or cardiovascular, neurological, ear, nose, and throat (ENT) (especially orthostatic hypotension and vestibular disorders), orthopaedic or musculoskeletal disorders,

  • Fitness level assessment: 35 ml/min./kg < VO2max < 55 ml/min./kg,

  • Non active smokers,

  • No alcohol, or drug addiction, and no medical treatment,

  • Covered by a Health Insurance System,

  • Having signed the informed consent,

  • Free from any engagement during the study.

Exclusion criteria

  • Any history or presence of clinically relevant cardiovascular, neurological or ENT (especially orthostatic hypotension and vestibular disorders), any chronic disease; any acute infectious disease, in particular

  • Symptomatic orthostatic hypotension whatever the decrease in blood pressure, or asymptomatic postural hypotension defined by a decrease in systolic blood pressure (SBP) equal to or greater than 20 mmHg within 3 minutes when changing from the supine to the standing position,

  • Cardiac rhythm disorders,

  • Hypertension,

  • Chronic back pains,

  • Vertebral fracture, scoliosis or herniated disc,

  • Glaucoma,

  • Self-reported hearing problems,

  • History of migraines,

  • History of hiatus hernia or gastro-esophageal reflux,

  • History of thyroid dysfunction, renal stones, diabetes,

  • History of head trauma,

  • History of genetic muscle and bone diseases of any kind,

  • Past records of thrombophlebitis, family history of thrombosis or positive response in thrombosis screening procedure (anti thrombin III, S-protein, C-protein, factor V Leiden mutation and the mutation 20210 of the prothrombin gene),

  • Signs of venous insufficiency, varicose veins, or telangiectasia

  • Bone mineral density: T-score ≤ -1.5,

  • Poor tolerance to blood sampling,

  • Having given whole blood (more than 7ml/kg) in a period of 8 weeks or less before the start of the experiment, or having given whole blood more than 5 times in the past 12 months,

  • Significant history of allergy, especially no dermatological allergy,

  • History of food allergy,

  • Significant anomaly detected in the biological analysis,

  • Positive reaction to any of the following tests: IgM antibodies for the Hepatovirus A (HVA IgM), Hepatitis B surface antigen (HBsAg), anti-Hepatovirus C antibodies (hepatitis C), antibodies to human immunodeficiency virus type 1 and 2,

  • Vegetarian or vegan,

  • Refusal to give permission to contact his general practitioner,

  • Subject who, in the judgment of the investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development,

  • Subject already participating or in the exclusion period of a clinical research,

  • Subject who has received more than 4500 Euros within 12 months for being a research subject,

  • Subject who cannot be contacted in case of emergency,

  • MRI contraindications History or active claustrophobia, Osteosynthesis material, presence of metallic implants or any other contra-indication for MRI, Allergy to Gadolinium.

  • Vulnerable persons according to law "Code de la Santé Publique" (L1121-5 to L1121-8) :

  • Pregnant women (urine pregnancy test performed at the selection visit and on the day of arrival in the facility),

  • Women during childbirth and breastfeeding mothers,

  • Persons deprived of their liberty by an administrative or judicial decision,

  • Persons under involuntary psychiatric care,

  • Persons admitted in a health or social establishment for purposes other than research,

  • Minors,

  • Adults subject to legal protection (subject under guardianship or trusteeship) or unable to express their consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medes-Imps Toulouse France 31400

Sponsors and Collaborators

  • Centre National d'Etudes Spatiales
  • European Space Agency

Investigators

  • Principal Investigator: Rebecca BILLETTE DE VILLEMEUR, MD, MEDES-IMPS

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre National d'Etudes Spatiales
ClinicalTrials.gov Identifier:
NCT05493176
Other Study ID Numbers:
  • 22-282
  • 2022-A00881-42
First Posted:
Aug 9, 2022
Last Update Posted:
Aug 9, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre National d'Etudes Spatiales

Study Results

No Results Posted as of Aug 9, 2022